OPCH Option Care Health (OPCH) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-home health care services · CIK 0001014739
Cluster · 4 insidersC-suite buying · 2Congress · 1
Funds added, last quarter
211
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $0 priced
What the filings say about OPCH
Insiders, 180 days
+$1.9M net bought
4 buyers
Congress, 1 year
1 bought · 1 sold
Latest: sale, 2025-10-31
Option Care Health insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Option Care Health, Inc. insiders bought a net $1.9M of stock across 50 Form 4 purchases and sales, with 4 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 4 earlier Form 4 trades (code P or S) here by this insider (1 buy, 3 sales), the last on Aug 21, 2025.
- The trade is 32.9% of the 73,383 shares held after it.
- 3 other insiders bought within 30 days.
- 211 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SULLIVAN TIMOTHY P bought about $499.7K of OPCH on May 7, 2026; 3 other insiders bought within 30 days and 211 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 buys), the last on Nov 3, 2025.
- +23.4% median (+13.8% mean) 90-day return after 7 previous buys.
- The trade is 8.1% of the 450,000 shares held after it.
- 3 other insiders bought within 30 days.
- 211 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director KRAEMER HARRY M JANSEN JR bought about $783.8K of OPCH on May 4, 2026; 3 other insiders bought within 30 days and 211 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 16.5% of the 98,337 shares held after it.
- 3 other insiders bought within 30 days.
- 211 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Sethna Meenal bought about $327.1K of OPCH on May 4, 2026; 3 other insiders bought within 30 days and 211 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 1.8% of the 695,152 shares held after it.
- 3 other insiders bought within 30 days.
- 211 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer RADEMACHER JOHN CHARLES bought about $264.8K of OPCH on May 4, 2026; 3 other insiders bought within 30 days and 211 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (2 buys, 7 sales), the last on Aug 20, 2025.
- -5.1% median (-5.1% mean) 90-day return after 2 previous buys.
- The trade is 260.6% of the 11,623 shares held after it.
- 1 other insider sold within 30 days.
- 211 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Pate R Carter sold about $970.7K of OPCH on Feb 27, 2026; 1 other insider sold within 30 days and 211 funds added in the latest 13F quarter.50 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$1.9M over 180 days
more than 95% of Healthcare Services
Congress
1 member bought in the last year
the lowest in Healthcare Services
Funds
211 funds bought in last quarter
more than 79% of Healthcare Services
Revenue
+13.0% year over year
more than 52% of Healthcare Services
Margin
3.7% net margin
more than 66% of Healthcare Services
Buybacks
$310.0M repurchased, FY to 2025-12-31
more than 84% of Healthcare Services
Short interest
5.8% of the float short (float per yahoo 2026-10-26) · 3.5 days to cover · settled 2026-09-30
more than 68% of Healthcare Services
What changed in the last 30 days
Oct 27Insider buying stopped: no purchases in 90 days after 4 in the prior 90
Why it matters
The absence is the signal: 4 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch OPCH
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+10.4%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns OPCH: institutional holders (13F)
13F holdings, latest reported quarter
22,104,863 sh
$463.5M
11,782,384 sh
$247.1M
8,274,458 sh
$173.5M
7,450,698 sh
$156.2M
7,063,747 sh
$148.1M
Congress trades in OPCH
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2025-10-31 · disclosed 21 days later
$1,001 - $15,000
Sold 2025-10-30 · disclosed 22 days later
$1,001 - $15,000
Bought 2025-10-30 · disclosed 22 days later
$1,001 - $15,000
Bought 2025-09-25 · disclosed 27 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
OPCH planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
OPCH mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
VistaShares Target 15 DRUKMacro Distribution ETF
$519.7K position · as of 2026-07-31
3.1%
Sovereign's Capital Flourish Fund
$2.4M position · as of 2026-07-31
2.7%
Villere Equity Fund
$704.4K position · as of 2026-05-31
2.2%
Villere Balanced Fund
$1.4M position · as of 2026-05-31
1.7%
State Street(R) SPDR(R) S&P(R) Health Care Services ETF
$2.2M position · as of 2026-06-30
1.6%
Nicholas Limited Edition, Inc.
$4.9M position · as of 2026-07-31
1.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Option Care Health, Inc. Pac
Cycle 2026 · $107K spent
$111.1K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Mr. Rademacher
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$16.6M
$22.2M
$3.6M
+126%
+22%
2022
$6.8M
$10.1M
$1.9M
+102%
+16%
2021
$8.4M
$13.1M
$3.3M
+91%
+46%
2020
$1.1M
$1.1M
$1.1M
+5%
+33%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
4 insiders reported buying shares.
The record shows a net $1.9M bought by insiders over 180 days, 211 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade. Each figure is a federal filing, dated the day it went public.
OPCH financials
Revenue growth
+13.0%
XBRL, annual
Net margin
3.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$5.7B
four quarters, 2025-04-01 to 2026-03-31
Revenue, TTM OPCH
| FY Dec 2025 | $5.6B |
| FY Dec 2024 | $5.0B |
| FY Dec 2023 | $4.3B |
| FY Dec 2022 | $3.9B |
| FY Dec 2021 | $3.4B |
| Mar 2026 | $1.4B |
| Dec 2025 | $1.5B |
| Sep 2025 | $1.4B |
| Jun 2025 | $1.4B |
| Mar 2025 | $1.3B |
| Dec 2024 | $1.3B |
| Sep 2024 | $1.3B |
| Jun 2024 | $1.2B |
At each fiscal year end
Single quarter
Net margin, TTM
+3.6%
net income over revenue, 2025-04-01 to 2026-03-31
Net margin, TTM OPCH
| FY Dec 2025 | +3.7% |
| FY Dec 2024 | +4.2% |
| FY Dec 2023 | +6.2% |
| FY Dec 2022 | +3.8% |
| FY Dec 2021 | +4.1% |
| Mar 2026 | +3.4% |
| Dec 2025 | +4.0% |
| Sep 2025 | +3.6% |
| Jun 2025 | +3.6% |
| Mar 2025 | +3.5% |
| Dec 2024 | +4.5% |
| Sep 2024 | +4.2% |
| Jun 2024 | +4.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$212.6M
operating cash flow minus capex, 2025-04-01 to 2026-03-31
Free cash flow, TTM OPCH
| FY Dec 2025 | $217.1M |
| FY Dec 2024 | $287.8M |
| FY Dec 2023 | $329.4M |
| FY Dec 2022 | $232.2M |
| FY Dec 2021 | $182.9M |
| Mar 2026 | -$21.2M |
| Dec 2025 | $22.2M |
| Sep 2025 | $130.2M |
| Jun 2025 | $81.2M |
| Mar 2025 | -$16.6M |
| Dec 2024 | $25.8M |
| Sep 2024 | $150.7M |
| Jun 2024 | $185.9M |
At each fiscal year end
Single quarter
Debt to equity
0.86x
long-term 2026-03-31 plus current 2026-03-31; equity 2026-03-31
Debt to equity OPCH
| FY Dec 2025 | 0.88x |
| FY Dec 2024 | 0.79x |
| FY Dec 2023 | 0.75x |
| FY Dec 2022 | 0.77x |
| FY Dec 2021 | 0.91x |
| Mar 2026 | 0.86x |
| Dec 2025 | 0.88x |
| Sep 2025 | 0.86x |
| Jun 2025 | 0.82x |
| Mar 2025 | 0.82x |
| Dec 2024 | 0.79x |
| Sep 2024 | 0.78x |
| Jun 2024 | 0.79x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.22x
TTM operating cash flow over long-term 2026-03-31 plus current 2026-03-31
Cash flow to debt OPCH
| FY Dec 2025 | 0.22x |
| FY Dec 2024 | 0.29x |
| FY Dec 2023 | 0.35x |
| FY Dec 2022 | 0.25x |
| FY Dec 2021 | 0.20x |
| Mar 2026 | 0.22x |
| Dec 2025 | 0.22x |
| Sep 2025 | 0.22x |
| Jun 2025 | 0.25x |
| Mar 2025 | 0.35x |
| Dec 2024 | 0.29x |
| Sep 2024 | 0.30x |
| Jun 2024 | 0.21x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+15.3%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on equity OPCH
| FY Dec 2025 | +15.2% |
| FY Dec 2024 | +15.0% |
| FY Dec 2023 | +19.0% |
| FY Dec 2022 | +11.8% |
| FY Dec 2021 | +12.8% |
| Mar 2026 | +15.3% |
| Dec 2025 | +15.2% |
| Sep 2025 | +15.0% |
| Jun 2025 | +15.2% |
| Mar 2025 | +15.4% |
| Dec 2024 | +15.0% |
| Sep 2024 | +14.6% |
| Jun 2024 | +14.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+6.2%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on assets OPCH
| FY Dec 2025 | +6.0% |
| FY Dec 2024 | +6.4% |
| FY Dec 2023 | +8.4% |
| FY Dec 2022 | +5.1% |
| FY Dec 2021 | +5.1% |
| Mar 2026 | +6.2% |
| Dec 2025 | +6.0% |
| Sep 2025 | +6.1% |
| Jun 2025 | +6.3% |
| Mar 2025 | +6.5% |
| Dec 2024 | +6.4% |
| Sep 2024 | +6.3% |
| Jun 2024 | +6.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+10.4%
operating income after a 26.5% effective tax rate, over long-term 2026-03-31 plus current 2026-03-31 plus average of 2025-03-31 and 2026-03-31 minus cash
Return on invested capital OPCH
| FY Dec 2025 | +11.3% |
| FY Dec 2024 | +11.2% |
| FY Dec 2023 | +10.9% |
| FY Dec 2022 | +8.2% |
| FY Dec 2021 | n/a |
| Mar 2026 | +10.4% |
| Dec 2025 | +11.3% |
| Sep 2025 | +11.4% |
| Jun 2025 | +11.1% |
| Mar 2025 | +10.6% |
| Dec 2024 | +11.2% |
| Sep 2024 | +11.2% |
| Jun 2024 | +11.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+12.6%
operating income (EBIT proxy) over average of 2025-03-31 and 2026-03-31 minus current liabilities
Return on capital employed OPCH
| FY Dec 2025 | +12.8% |
| FY Dec 2024 | +12.3% |
| FY Dec 2023 | +12.2% |
| FY Dec 2022 | +9.8% |
| FY Dec 2021 | +8.4% |
| Mar 2026 | +12.6% |
| Dec 2025 | +12.8% |
| Sep 2025 | +12.5% |
| Jun 2025 | +12.7% |
| Mar 2025 | +12.8% |
| Dec 2024 | +12.3% |
| Sep 2024 | +12.1% |
| Jun 2024 | +11.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
24.39x
close 2026-10-23 over four quarters of diluted EPS, 2025-04-01 to 2026-03-31
P/E, trailing OPCH
| FY Dec 2025 | 25.09x |
| FY Dec 2024 | 18.86x |
| FY Dec 2023 | 22.92x |
| FY Dec 2022 | 36.25x |
| FY Dec 2021 | 36.94x |
| Mar 2026 | 21.03x |
| Dec 2025 | 25.09x |
| Sep 2025 | 21.86x |
| Jun 2025 | 25.78x |
| Mar 2025 | 27.96x |
| Dec 2024 | 18.86x |
| Sep 2024 | 26.30x |
| Jun 2024 | 23.28x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$5.9B
market value at close 2026-10-23 on 2026-04-28 shares, plus long-term 2026-03-31 plus current 2026-03-31, minus cash 2026-03-31
Enterprise value OPCH
| FY Dec 2025 | $6.0B |
| FY Dec 2024 | $4.6B |
| FY Dec 2023 | $6.7B |
| FY Dec 2022 | $6.2B |
| FY Dec 2021 | $6.1B |
| Mar 2026 | $5.2B |
| Dec 2025 | $6.0B |
| Sep 2025 | $5.4B |
| Jun 2025 | $6.2B |
| Mar 2025 | $6.7B |
| Dec 2024 | $4.6B |
| Sep 2024 | $6.0B |
| Jun 2024 | $5.5B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+4.3%
TTM free cash flow over market value at close 2026-10-23
FCF yield OPCH
| FY Dec 2025 | +4.3% |
| FY Dec 2024 | +7.3% |
| FY Dec 2023 | +5.5% |
| FY Dec 2022 | +4.2% |
| FY Dec 2021 | +3.6% |
| Mar 2026 | +5.0% |
| Dec 2025 | +4.3% |
| Sep 2025 | +4.9% |
| Jun 2025 | +4.5% |
| Mar 2025 | +6.0% |
| Dec 2024 | +7.3% |
| Sep 2024 | +5.5% |
| Jun 2024 | +4.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
10.16x
P/E over trailing EPS growth of 2%: four quarters to 2026-03-31 against the four to 2025-03-31
PEG, trailing OPCH
| FY Dec 2025 | 7.71x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 0.30x |
| FY Dec 2022 | 4.65x |
| FY Dec 2021 | n/a |
| Mar 2026 | 8.76x |
| Dec 2025 | 7.71x |
| Sep 2025 | 3.25x |
| Jun 2025 | 4.38x |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $5.6B | $5.0B | $4.3B | $3.9B |
| Gross profit | $1.1B | $1.0B | $981.2M | $866.9M |
| Operating income | $337.9M | $321.8M | $314.6M | $240.2M |
| Net income | $207.6M | $211.8M | $267.1M | $150.6M |
| EPS (diluted) | 1.27 | 1.23 | 1.48 | 0.83 |
| Operating cash flow | $258.4M | $323.4M | $371.3M | $267.5M |
| Cash | $232.6M | $412.6M | $343.8M | $294.2M |
| Long-term debt | $1.2B | $1.1B | $1.1B | $1.1B |
| Buybacks | $310.0M | $252.7M | $250.3M | $0 |
SEC XBRL, fiscal years, as known on 2026-10-27
OPCH Stock Sonar score 6/7 axes
Find similar shapesCompareOPCH ranks highest on insider conviction (97th percentile) and profitability (68th), and lowest on financial health (44th), among Healthcare Services peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
OPCH filings, in plain words
Are Option Care Health insiders buying or selling OPCH?
In the 180 days to 2026-10-27, Option Care Health insiders were net buyers, a net $1.9M across purchases and sales reported on Form 4, by 4 buyers.
Have members of Congress traded OPCH?
Yes. In the year to 2026-10-27, 1 House member disclosed buying OPCH and 1 House member disclosed selling it; the latest on record is a sale by Lisa McClain dated 2025-10-31.
Read the full summary
In the 180 days to 2026-10-27, Option Care Health insiders were net buyers of OPCH, a net $1.9M across purchases and sales reported on Form 4 by 4 buyers. 4 insiders reported purchases in that window. In the year to 2026-10-27, 1 member of Congress disclosed buying OPCH and 1 member disclosed selling it; the latest on record is a sale by Lisa McClain dated 2025-10-31. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
